Chiesi USA, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$76.1M
Doctors Paid
27,496
Transactions
90,315
2024 Total
$12.5M
Payment Breakdown by Category
Research$57.2M (75.1%)
Consulting$4.7M (6.1%)
Food & Beverage$1.8M (2.4%)
Royalty/License$1.7M (2.3%)
Travel$1.0M (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $57.2M | 15,127 | 75.1% |
| Consulting Fee | $4.7M | 842 | 6.1% |
| Grant | $3.6M | 168 | 4.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 1,315 | 4.2% |
| Food and Beverage | $1.8M | 62,747 | 2.4% |
| Royalty or License | $1.7M | 4 | 2.3% |
| Honoraria | $1.7M | 825 | 2.2% |
| Travel and Lodging | $1.0M | 3,282 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $812,666 | 530 | 1.1% |
| Charitable Contribution | $202,550 | 54 | 0.3% |
| Education | $92,612 | 4,503 | 0.1% |
| Gift | $61,925 | 918 | 0.1% |
Payments by Type
Research
$57.2M
15,127 transactions
General
$19.0M
75,188 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | $10.2M | 1 | 3,691 |
| CCD-05993AA3-02 | $9.6M | 0 | 2,209 |
| A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | $8.7M | 0 | 1,274 |
| CCD-05993AA3-01 | $6.9M | 0 | 1,769 |
| A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. | $5.2M | 0 | 2,136 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) | $2.6M | 0 | 640 |
| CCD-05993AA3-03 | $1.7M | 0 | 117 |
| A 52-WEEK, PLACEBO- AND ACTIVE- CONTROLLED (ROFLUMILAST, DALIRESP 500) STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSES OF CHF6001 DPI (TANIMILAST) AS ADD-ON TO MAINTENANCE TRIPLE THERAPY IN SUBJECTS WITH COPD AND CHRONIC BRONCHITIS. (PILLAR) (PI | $1.7M | 0 | 351 |
| Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients | $1.1M | 0 | 161 |
| CCD-5633AA1-02 | $926,271 | 0 | 265 |
| OPEN-LABEL EXPANDED ACCESS TREATMENT WITH PEGUNIGALSIDASE ALFA FOR FABRY DISEASE PATIENTS | $765,833 | 0 | 134 |
| A STUDY COMPARING EFFICACY, SAFETY AND TOLERABILITY OF THE FIXED DOSE TRIPLE COMBINATION CHF 5993 WITH THE FIXED DOSE DUAL COMBINATION CHF 1535 IN SUBJECTS WITH COPD (TRITON) | $628,732 | 0 | 112 |
| A STUDY IN PRETERM NEONATES WITH RDS TO COMPARE CUROSURF ADMINISTRATION THROUGH LISA AND CONVENTIONAL ADMINISTRATION (LISPAP) | $566,842 | 0 | 117 |
| RegistryStudyofRevcoviTreatment in Patients With ADA-SCID | $440,845 | 0 | 23 |
| Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | $431,994 | 0 | 311 |
| A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER) | $422,258 | 0 | 56 |
| DPM-CF-303 | $307,459 | 12 | 83 |
| CUSA-081-HEM-01 | $293,715 | 1 | 112 |
| PRO00038725 | $263,334 | 0 | 103 |
| Pro00038725 | $242,491 | 0 | 86 |
| A 12 WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP STUDY TESTING THE SUPERIORITY OF CHF 1535 PMDI 800/24 TOTAL DAILY DOSE (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) COMPAR | $216,954 | 1 | 76 |
| NONE | $211,535 | 18 | 55 |
| CAMEO | $184,929 | 0 | 40 |
| Pro00038731 | $169,966 | 0 | 31 |
| Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy | $145,400 | 0 | 35 |
| CLI-06563AA1-02 | $133,915 | 8 | 60 |
| A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the Use ofCUSA-081for Dysfunctional Central Venous Access Devices (CVADs) | $117,381 | 0 | 108 |
| READY-1 (CUSA-081) | $104,377 | 0 | 110 |
| A Study in Preterm Neonates With RDS to Compare CUROSURF? Administration Through LISA and Conventional Administration (LISPAP) | $98,254 | 0 | 36 |
| Efficacy and Safety ofCUSA-081in the Restoration of Central Venous Access Device (CVAD) Functionality (READY1) | $78,854 | 0 | 58 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Marianne Mann, Md, MD | Internal Medicine | Highland, MD | $2.0M | $0 |
| Dr. William Alexander, Md, MD | Infectious Disease | Cary, NC | $491,689 | $0 |
| Todd Horowitz, Do, DO | Anesthesiology | Delray Beach, FL | $430,110 | $0 |
| David Rose, M.d, M.D | Neurology | Tampa, FL | $384,592 | $0 |
| David Kong, M.d., A.m., D.m.t, M.D., A.M., D.M.T | Cardiovascular Disease | Durham, NC | $352,496 | $0 |
| Dr. Gerald Cox, Md, Phd, MD, PHD | Clinical Genetics (M.D.) | Boston, MA | $236,100 | $0 |
| Edward Obrien, Md, MD | Anesthesiology | San Diego, CA | $212,987 | $0 |
| Dawn Meyer | Family | San Diego, CA | $184,064 | $0 |
| Dr. Scott Brehaut, Md, MD | Family Medicine | Clinton, NY | $183,282 | $0 |
| Dr. Rajesh Dave, M.d, M.D | Interventional Cardiology | Camp Hill, PA | $173,569 | $0 |
| Dr. Edwin Avery, Md, MD | Anesthesiology | Cleveland, OH | $151,494 | $0 |
| Megha Prasad, Md, MD | Internal Medicine | New York, NY | $150,344 | $0 |
| Rangasamy Ramanathan, Md, MD | Neonatal-Perinatal Medicine | West Hollywood, CA | $136,785 | $0 |
| Lance Parton, Md, MD | Neonatal-Perinatal Medicine | Valhalla, NY | $117,629 | $0 |
| Danny Stewart, Md, MD | Pediatrics | Louisville, KY | $116,271 | $0 |
| Dr. Thomas Stuckey, M.d, M.D | Cardiovascular Disease | Greensboro, NC | $115,117 | $0 |
| Dr. Fariborz Rezai, M.d, M.D | Internal Medicine | Livingston, NJ | $115,057 | $0 |
| Dr. Ali Seifi, Md, MD | Neurocritical Care | San Antonio, TX | $96,920 | $0 |
| Miguel Diaz, Md, MD | Internal Medicine | Hialeah, FL | $96,189 | $0 |
| Dr. Robert Jobe, M.d, M.D | Cardiovascular Disease | Raleigh, NC | $85,772 | $0 |
| Dr. Henry Wojtczak, M.d, M.D | Pediatric Pulmonology | Albuquerque, NM | $81,980 | $0 |
| Dr. Mitul Patel, M.d, M.D | Cardiovascular Disease | San Diego, CA | $77,804 | $0 |
| David Warnock, Md, MD | Nephrology | Birmingham, AL | $73,629 | $0 |
| James Moore, Md Phd, MD PHD | Neonatal-Perinatal Medicine | Hartford, CT | $71,875 | $0 |
| Dr. May Kim-Tenser, Md, MD | Neurology | Los Angeles, CA | $65,235 | $0 |
Ad
Top Products
- KENGREAL $4.3M
- CLEVIPREX $3.8M
Associated Products (22)
- KENGREAL $4.3M
- CLEVIPREX $3.8M
- CUROSURF $2.5M
- TIOTROPIUM BROMIDE $2.2M
- REVCOVI $788,966
- FERRIPROX $760,853
- BECLOMETHASONE DIPROPIONATE $733,851
- LAMZEDE $309,480
- RETAVASE $293,683
- Poractant Alfa $266,292
- PERTZYE $209,477
- BETHKIS $189,401
- ELFABRIO $156,816
- CARDENE $108,069
- FILSUVEZ $104,711
- PORACTANT ALFA / CUROSURF $89,989
- BRONCHITOL $62,726
- FORMOTEROL $59,338
- KENGREAL 50MG/10ML L $36,320
- CLEVIPREX 25MG/50ML $29,526
- Curosurf $20,947
- CLEVIPREX 50MG/100ML $14,083
Payment Categories
- Food & Beverage $1.8M
- Consulting $4.7M
- Travel & Lodging $1.0M
- Research $57.2M
- Royalties $1.7M
About Chiesi USA, Inc.
Chiesi USA, Inc. has made $76.1M in payments to 27,496 healthcare providers, recorded across 90,315 transactions in the CMS Open Payments database. In 2024, the company paid $12.5M. The top product by payment volume is KENGREAL ($4.3M).
Payments were distributed across 207 medical specialties. The top specialty by payment amount is Internal Medicine ($3.0M to 2,738 doctors).
Payment categories include: Food & Beverage ($1.8M), Consulting ($4.7M), Research ($57.2M), Travel & Lodging ($1.0M), Royalties ($1.7M).
Chiesi USA, Inc. is associated with 22 products in the CMS Open Payments database, including KENGREAL, CLEVIPREX, and CUROSURF.